Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Moderna (Nasdaq: MRNA) will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12 at 7:30 p.m. ET / 4:30 p.m. PT. A live webcast will be available under "Events and Presentations" in the Investors section at investors.modernatx.com. A replay will be archived on Moderna's website for at least 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction 17 Alerts
On the day this news was published, MRNA gained 2.07%, reflecting a moderate positive market reaction. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $251M to the company's valuation, bringing the market cap to $12.38B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed, mostly modest gains (e.g., ROIV +4.99%, HALO +1.95%) while MRNA was roughly flat at -0.1%, suggesting this conference appearance is stock-specific rather than part of a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Regulatory opinion | Positive | +1.6% | EMA committee issued positive opinion for mNEXSPIKE COVID-19 vaccine. |
| Nov 20 | Strategy update | Positive | -7.5% | Analyst Day outlined growth strategy, cost reductions, and pipeline plans. |
| Nov 20 | Financing facility | Positive | -7.5% | Announced up to $1.5B non-dilutive term loan facility with Ares. |
| Nov 19 | Manufacturing expansion | Positive | -3.0% | Onshoring U.S. Drug Product manufacturing with >$140M investment. |
| Nov 18 | Conference appearance | Neutral | +0.7% | Announced presentation at Piper Sandler healthcare conference with webcast. |
Recent news includes positive regulatory and strategy updates plus neutral conference appearances, with price reactions mixed: some positive regulatory outcomes saw modest gains, while strategic and financing updates sometimes coincided with declines.
Over the last few months, Moderna reported multiple notable events, including a positive EMA opinion for mNEXSPIKE on Dec 15 with a +1.56% reaction, strategy and financing updates on Nov 20 tied to an Analyst Day and a $1.5B term loan, and U.S. manufacturing expansion on Nov 19. It also announced another conference appearance on Nov 18 with a small gain. Today’s J.P. Morgan conference notice fits into this pattern of frequent investor and strategic communications.
Market Pulse Summary
This announcement highlights Moderna’s participation in the 44th J.P. Morgan Healthcare Conference on January 12, with a webcast at 7:30 p.m. ET and a replay available for 30 days. It follows a series of recent regulatory, strategic, and financing updates. Investors tracking the story may focus on what new detail, if any, the company provides at the conference about its pipeline, cost structure, and capital position, relative to the information already disclosed in recent filings and events.
AI-generated analysis. Not financial advice.
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ET / 4:30 p.m. PT.
A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.
A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Moderna (MRNA) present at the J.P. Morgan Healthcare Conference?
How can investors watch Moderna's (MRNA) presentation on January 12?
Will Moderna (MRNA) provide a replay of its J.P. Morgan presentation?
What time is Moderna's (MRNA) presentation in Pacific Time?
Where on Moderna's site is the webcast for the J.P. Morgan presentation hosted?
Does Moderna (MRNA) require registration to view the live webcast on January 12?
